Drug target Mendelian randomisation: are we really instrumenting drug use? Reply to Anderson EL, Williams DM [letter].
作者信息
Zheng Jie, Gaunt Tom R, Xu Min, Smith George Davey, Bi Yufang
机构信息
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Shanghai Digital Medicine Innovation Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
出版信息
Diabetologia. 2023 Jun;66(6):1159-1161. doi: 10.1007/s00125-023-05892-w. Epub 2023 Mar 10.
Abstract
摘要
相似文献
1
Drug target Mendelian randomisation: are we really instrumenting drug use? Reply to Anderson EL, Williams DM [letter].药物靶点孟德尔随机化：我们真的在为药物使用设定工具变量吗？对安德森·E·L、威廉姆斯·D·M的回复[信函]
Diabetologia. 2023 Jun;66(6):1159-1161. doi: 10.1007/s00125-023-05892-w. Epub 2023 Mar 10.
2
Drug target Mendelian randomisation: are we really instrumenting drug use?药物靶点孟德尔随机化：我们真的在对药物使用进行工具变量设定吗？
Diabetologia. 2023 Jun;66(6):1156-1158. doi: 10.1007/s00125-023-05875-x. Epub 2023 Feb 16.
3
Dementia prevention: the Mendelian randomisation perspective.痴呆症预防：孟德尔随机化视角。
J Neurol Neurosurg Psychiatry. 2024 Mar 13;95(4):384-390. doi: 10.1136/jnnp-2023-332293.
4
Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals.2 型糖尿病与痴呆风险：100 万人的观察性和孟德尔随机化研究。
Epidemiol Psychiatr Sci. 2020 Apr 24;29:e118. doi: 10.1017/S2045796020000347.
5
Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study.评估二甲双胍靶点降低普通人群阿尔茨海默病风险的疗效和机制：一项孟德尔随机研究。
Diabetologia. 2022 Oct;65(10):1664-1675. doi: 10.1007/s00125-022-05743-0. Epub 2022 Jul 29.
6
Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study.在英国生物银行中评估二甲双胍的靶点AMPK激活对心血管疾病和癌症风险的影响：一项孟德尔随机化研究。
Diabetologia. 2020 Nov;63(11):2349-2358. doi: 10.1007/s00125-020-05243-z. Epub 2020 Aug 4.
7
Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis.血浆尿酸浓度与冠心病风险：孟德尔随机分析。
Lancet Diabetes Endocrinol. 2016 Apr;4(4):327-36. doi: 10.1016/S2213-8587(15)00386-1. Epub 2016 Jan 16.
8
[Mendelian randomisation].[孟德尔随机化]
Ned Tijdschr Geneeskd. 2014;158:A7547.
9
[Mendelian randomisation - a genetic approach to an epidemiological method].[孟德尔随机化——一种流行病学方法的遗传学途径]
Tidsskr Nor Laegeforen. 2016 Jun 21;136(11):1002-5. doi: 10.4045/tidsskr.15.1262. eCollection 2016 Jun.
10
Mendelian randomisation in cardiovascular research: an introduction for clinicians.心血管研究中的孟德尔随机化：临床医生入门指南
Heart. 2017 Sep;103(18):1400-1407. doi: 10.1136/heartjnl-2016-310605. Epub 2017 Jun 8.
本文引用的文献
1
Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study.评估二甲双胍靶点降低普通人群阿尔茨海默病风险的疗效和机制：一项孟德尔随机研究。
Diabetologia. 2022 Oct;65(10):1664-1675. doi: 10.1007/s00125-022-05743-0. Epub 2022 Jul 29.
2
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development.将基因组学与生物标志物和治疗靶点相结合，激发心血管药物研发。
Nat Rev Cardiol. 2021 Jun;18(6):435-453. doi: 10.1038/s41569-020-00493-1. Epub 2021 Mar 11.
3
Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?二甲双胍的益处：另一个关于替代能源底物机制的例子？
Diabetes Care. 2021 Mar;44(3):647-654. doi: 10.2337/dc20-1964.
4
Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study.二甲双胍的使用与 2 型糖尿病老年患者认知能力下降减缓及痴呆发生减少相关：悉尼记忆与老龄化研究。
Diabetes Care. 2020 Nov;43(11):2691-2701. doi: 10.2337/dc20-0892. Epub 2020 Sep 23.
5
Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.遗传介导的 HMG-CoA 还原酶抑制与上皮性卵巢癌的关联。
JAMA. 2020 Feb 18;323(7):646-655. doi: 10.1001/jama.2020.0150.
Zotero 插件